| A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME | diabetic macular edema | Active, not recruiting | Phase 3 | 2026-10-08 | | NCT04108156 |
|---|
| Continuous Delivery of Ranibizumab Via the Port Delivery System for Proliferative Diabetic Retinopathy-related Vitreous Hemorrhage With Pars Plana Vitrectomy and Limited PRP. | Diabetes Complications, Nutritional and Metabolic Diseases, cardiovascular disorder, diabetes mellitus, diabetic peripheral angiopathy, diabetic retinopathy, endocrine system disorder, eye disorder, glucose metabolism disease, metabolic disease, retinal disorder, vascular disorder | Not yet recruiting | Phase 4 | 2026-10-07 | | NCT07864480 |
|---|
| A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01 | Diabetes Complications, cardiovascular disorder, diabetes mellitus, diabetic peripheral angiopathy, diabetic retinopathy, endocrine system disorder, eye disorder, retinal disorder, vascular disorder | Active, not recruiting | Phase 2 | 2026-10-02 | | NCT06770933 |
|---|
| Extension Study for the Port Delivery System With Ranibizumab (Portal) | Neovascular Age-Related Macular Degeneration | Recruiting | Phase 3 | 2026-09-28 | | NCT03683251 |
|---|
| A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy | Geographic Atrophy, eye disorder, macular degeneration, retinal degeneration, retinal disorder | Recruiting | Phase 3 | 2026-09-18 | | NCT06541704 |
|---|
| An Observational Study of the Progression of Intermediate Age-Related Macular Degeneration | age-related macular degeneration, eye disorder, macular degeneration, retinal degeneration, retinal disorder | Active, not recruiting | Not stated | 2026-09-16 | | NCT05300724 |
|---|
| Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD) | Neovascular Age-related Macular Degeneration (nAMD) | Active, not recruiting | Phase 1 / Phase 2 | 2026-08-27 | | NCT05769153 |
|---|
| A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio | Geographic Atrophy Secondary to Age-related Macular Degeneration | Recruiting | Phase 2 | 2026-06-24 | | NCT07215390 |
|---|
| 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | eye disorder, macular degeneration, retinal degeneration, retinal disorder, wet macular degeneration | Active, not recruiting | Phase 3 | 2026-06-01 | | NCT06864988 |
|---|
| A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK | Wet Age-related Macular Degeneration | Active, not recruiting | Phase 3 | 2026-04-29 | | NCT06556368 |
|---|
| Evaluation of Tonabersat for DME | diabetic macular edema | Active, not recruiting | Phase 2 | 2025-12-11 | | NCT05727891 |
|---|
| Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration | Neovascular Age-Related Macular Degeneration (nAMD) | Active, not recruiting | Phase 2 | 2025-10-30 | | NCT06116890 |
|---|
| Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration | Neovascular Age-related Macular Degeneration | Active, not recruiting | Phase 3 | 2025-06-17 | | NCT06495918 |
|---|